Cross-trial scans favor tirzepatide: semaglutide measured about 62:38 fat-to-lean loss versus roughly 75:25 for tirzepatide. The scan overstates muscle loss, however, because lean mass includes water and organs
No differences were observed in islet histology, islet size or fluorescent intensity of insulin, glucagon or somatostatin (Extended Data Fig
Weight loss medications may make you lose your appetite and cravings for food, but they wont touch the underlying root causes of why you turned to food to soothe
Patients should be advised to report new or worsening neurological symptoms promptly, as these may indicate progressive deficiency requiring more aggressive intervention
The obesity drug Wegovy showed the strongest link to ischemic optic neuropathy, even though it had fewer overall reports than Ozempic, the diabetes formulation
10 , e020734 (2021)